Diabetes drugs like ozempic reduce cancer risk

A class of diabetes medications, which includes the popular drug Ozempicis associated with a lower risk of certain obesity-related cancers.

The researchers, led by Rong Xu of Case Western Reserve University School of Medicine in Cleveland, Ohio, found that patients who received GLP-1 agonists had a significantly lower risk of developing 10 of the 13 types of cancer studiedincluding kidney, pancreatic, esophageal, ovarian, liver, and colorectal cancer.

Cancers that showed no significant change in risk included thyroid cancer and breast cancer in postmenopausal women.

«Obesity is known to be associated with at least 13 types of cancer“,” Xu said. “Our study provides evidence that GLP-1 agonists hold promise for breaking the link between obesity and cancer,” he said.

Among the drugs studied are: semaglutida (marketed as Ozempic), as well as liraglutide and others.

GLP-1 agonists have been around for about 20 years, but a new generation of these drugs, including Ozempic, has gained popularity for its more significant weight loss effects.

Xu suggested that the protective benefits demonstrated in the study could encourage doctors to prescribe GLP-1 agonist treatments for patients with diabetes instead of other medications such as insulin.

 
For Latest Updates Follow us on Google News
 

-

PREV Totalplay discounts 500 pesos on its rates for these customers
NEXT Karol G’s moving rendition of the Colombian anthem at the 2024 Copa América final